Judah Frommer

Stock Analyst at Morgan Stanley

(3.05)
# 472
Out of 5,356 analysts
193
Total ratings
60.00%
Success rate
35.39%
Average return
43 Stocks
Name Action PT Current % Upside Ratings Updated
BPMC Blueprint Medicines
Maintains: Equal-Weight
102 129
127.86 0.89% 2 Jun 5, 2025
CLDX Celldex Therapeutics
Maintains: Overweight
46 43
19.52 120.29% 2 May 9, 2025
ABVX Abivax
Assumes: Equal-Weight
12
8.13 47.6% 1 Mar 20, 2025
RGNX Regenxbio
Maintains: Overweight
22 24
8.47 183.35% 2 Mar 14, 2025
GLPG Galapagos
Downgrades: Underweight
31 22
27.96 -21.32% 3 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
8 6
3.88 54.64% 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
31
19.11 62.22% 1 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
81 106
66.33 59.81% 2 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
35
11.07 216.17% 1 Oct 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
2.58 403.88% 1 Apr 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Equal-Weight
3
0.78 284.62% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
40
5.66 606.71% 8 Aug 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
4
n/a n/a 3 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.07 1114.95% 5 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30
35.69 -15.94% 8 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
23
10.91 110.82% 5 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
50
51.76 -3.4% 9 Jul 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
141
39.13 260.34% 13 Jun 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.3 900% 5 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
9
2.46 265.85% 5 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
175 138
n/a n/a 6 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
21 22
19.51 12.76% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
8 7
5.58 25.45% 3 Mar 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 1
n/a n/a 4 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
11 8
7.11 12.52% 5 Mar 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
12.9 256.59% 5 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
7 7
1.16 503.45% 6 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
51 55
16.77 227.97% 3 Feb 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
72.72 -36.74% 1 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
4 4
n/a n/a 1 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
14 10
n/a n/a 2 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
47 49
87.71 -44.13% 4 Nov 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
328 370
1010.29 -63.38% 2 Oct 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 31
77.53 -60.02% 6 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 76
73.72 3.09% 8 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
182
113.82 59.9% 6 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
107
96.62 10.74% 13 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
90 95
114.94 -17.35% 10 Jul 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
18
21.55 -16.47% 1 Jul 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
93 116
127.78 -9.22% 12 Jun 10, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
31 38
108.94 -65.12% 4 May 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 22
167.98 -86.9% 1 May 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
33 35
66.11 -47.06% 9 Apr 29, 2020